(A) Western blot analysis of expressions of integrin subunits α, βand βin HEK293(β) and HEK293(β) cell lines

<p><b>Copyright information:</b></p><p>Taken from "optical imaging of integrin α-βin mice using multivalent or monovalent cRGD targeting vectors"</p><p>http://www.molecular-cancer.com/content/6/1/41</p><p>Molecular Cancer 2007;6():41-41.</p><p>Published online 12 Jun 2007</p><p>PMCID:PMC1906830.</p><p></p> (B) Confocal laser scanning microscopic images of HEK293(β) and HEK293(β) cells incubated for 30 min at 37°C in the presence of 0.1 μM Cy5-labeled RAFT-c(-RGDfK-), cRGD, or RAFT-c(-RβADfK). Nuclei were stained with Hoechst 33342 (blue), and fluorescence signal from Cy5 was pseudocolored red. Original objective: Plan-Neofluar 40x/1.30 Oil ph3

Additional file 6: of Uniform intratumoral distribution of radioactivity produced using two different radioagents, 64Cu-cyclam-RAFT-c(-RGDfK-)4 and 64Cu-ATSM, improves therapeutic efficacy in a small animal tumor model

(a) Tumor growth ratios of the same set of treated groups as described in Fig. 3. *, †, ‡P < 0.05 for combination, 64Cu-RaftRGD, and 64Cu-ATSM vs. vehicle control, respectively. Tumor growth ratios (b) and body weight changes (c) of U87MG tumor-bearing mice after co-administration of 64Cu-RaftRGD and 64Cu-ATSM at 111 MBq (55.5 MBq for each agent) and 148 MBq (74 MBq for each agent). Values are the means ± standard deviations (n = 4/group). *, **P < 0.05 and 0.01, respectively for 111 MBq-group vs. 148 MBq group, respectively. It should be noted that although vehicle controls (b, c) were not performed simultaneously along with the 111 MBq and 148 MBq groups, all the three independent experiments (#1 and #2 extracted from Additional file 4 and Additional file 6a, respectively) showed a reproducibly steady increase of the tumor volume in the vehicle-treated mice. (PDF 337 kb

Additional file 3: of Uniform intratumoral distribution of radioactivity produced using two different radioagents, 64Cu-cyclam-RAFT-c(-RGDfK-)4 and 64Cu-ATSM, improves therapeutic efficacy in a small animal tumor model

Intratumoral distribution of 64Cu-ATSM and microvasculature. An adjacent slice to that presented in Fig. 2b was examined by autoradiography, CD31 immunofluorescence staining, and HE staining. Merged image showing 64Cu-ATSM distribution in green, CD31-stained microvessels in red, and HE stains. High-resolution pictures shown by dotted rectangles clearly depicting the stained microvessels in smaller size in 64Cu-ATSM high- vs. low-accumulated areas. Nuclei were stained with DAPI (blue). Scale bars, 2 mm, 200 μm. (PDF 285 kb

Additional file 5: of Uniform intratumoral distribution of radioactivity produced using two different radioagents, 64Cu-cyclam-RAFT-c(-RGDfK-)4 and 64Cu-ATSM, improves therapeutic efficacy in a small animal tumor model

Tumor growth curves (a) and body weight changes (b) of the same set of experimental groups as described in Fig. 3. Values are the means ± standard deviations (n = 6/group). The final data points shown for each group of mice (b) represent the results obtained at survival endpoint days (represented by a mean value). *, †, ‡P < 0.05 for combination, 64Cu-RaftRGD, and 64Cu-ATSM vs. vehicle control, respectively. (PDF 140 kb

CTOS growth in various culture conditions.

<p>(A) Growth curve of CTOS cultured in StemPro hESC (Invitrogen) or basal medium containing one of the growth factors as indicated. (B) Representative images of CTOS at day 14 in (A).</p

<i>In vitro</i> assays of radiolabeled anti-HER3 antibody Mab#58.

<p>(A) Cell binding assay for [⁸⁹Zr]Mab#58 comparing HER3 overexpressing HER3/RH7777 cells (closed triangles) and parent RH7777 cells (closed circles). (B) Competitive inhibition assay for DF-conjugated (closed circles) and unconjugated Mab#58 (closed squares). (C) Internalization assay for [⁸⁹Zr]Mab#58 at 37°C. Changes in the percentage of total radioactivity for each fraction are plotted against incubation time at 37°C (closed circles, internalized fraction; open triangles, membrane-bound fraction; open circles, protein-bound fraction in the culture medium; closed triangles, non-protein-bound fraction in the culture medium). These assays were conducted in duplicate. Data represent the mean.</p

Representative immunohistochemical staining of HER3/RH7777 (A) and RH7777 (B) xenografts for HER3 expression.

<p>Representative immunohistochemical staining of HER3/RH7777 (A) and RH7777 (B) xenografts for HER3 expression.</p

Representative PET images of mice bearing both HER3 overexpressing HER3/RH7777 and parent RH7777 xenografts.

<p>Serial PET images (maximum-intensity-projection (MIP)) of a mouse bearing HER3/RH7777 (right thigh, white arrow) and RH7777 (left thigh, orange arrow) tumors at days 1, 2, 4, and 6 after an intravenous injection of 3.7 MBq [⁸⁹Zr]Mab#58.</p

Representative PET images of mice bearing CTOS C45 xenografts.

<p>Serial PET images of mice bearing C45 xenograft (white arrow) injected with [⁸⁹Zr]Mab#58 (upper panels) or similarly ⁸⁹Zr-labeled control IgG.</p

Representative immunohistochemical staining of CTOS C45 xenograft for HER3 expression.

<p>Representative immunohistochemical staining of CTOS C45 xenograft for HER3 expression.</p